article thumbnail

MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation

Cannabis Law Report

Studies estimate that the number of people suffering from rheumatoid arthritis may rise to over 78 million by 2040. The rising prevalence of rheumatoid arthritis, psoriatic arthritis, and inflammatory bowel disease are driving demand for TNF inhibitors like MYMD-1. Chapman has operated Chapman Pharmaceutical Consulting, Inc.,